- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Neurofibromatosis type 1 (NF1)
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.7MB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 2.1MB)
Selumetinib – November 2022
Selumetinib: Capsule 10 mg, Capsule 25 mg; Koselugo®
Last updated
17 March 2023